E
PRTK

Ergoteles’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Ergoteles’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-26,601
Closed -$49.7K – 1936
2022
Q4 		$49.7K Sell
26,601
-82,312
-76% -$205K ﹤0.01% 1293
2022
Q3 		$280K Sell
108,913
-119,287
-52% -$297K 0.01% 1013
2022
Q2 		$440K Buy
+228,200
New +$498K 0.01% 897

Other funds holding PRTK

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Ergoteles's PRTK Position: Q1 2023 in Review

Ergoteles sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2023, closing a stake of 26,601 shares — an estimated $49.7K sold.

Ergoteles first reported a position in PRTK in Q2 2022 and held it in 3 quarters. The position peaked at $440K in Q2 2022. 63 funds tracked by Wall St. Rank hold PRTK as of Q1 2023.

  • Ergoteles reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 26,601 Paratek Pharmaceuticals, Inc. shares in Q1 2023, an estimated $49.7K.
  • Ergoteles first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2022 and held it in 3 quarters.
  • Ergoteles's Paratek Pharmaceuticals, Inc. position peaked at $440K in Q2 2022.
  • 63 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.